Previous 10 | Next 10 |
Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr. Leonid Metelitsa in harn...
R. R. Donnelley & Sons (NYSE:RRD) +31%. Inhibrx (NASDAQ:INBX) +17% on favorable safety profile in patients with alpha-1 antitrypsin deficiency and demonstrates the potential to achieve normal alpha-1 antitrypsin levels with monthly dosing. Protara Therapeutics (NASDAQ:TARA) +26%...
BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type ...
Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany AK is one of the most common diagnoses made by dermatologists in Europe and Almir...
Insiders Consider These Penny Stocks To Buy Right Now Are insiders something that you follow in the market when it comes to penny stocks? Some consider this strategy “following the money” and has lead to a new trend among retail traders. Mimicking the actions of larger inv...
BUFFALO, N.Y., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of data ...
BUFFALO, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and...
Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine ...
Athenix, Inc. (ATNX) Q2 2021 Earnings Conference Call August 5, 2021 08:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Rudolf Kwan - Chief Medical Officer Randoll Sze - Chief Financial Officer Dan Lang ...
Image source: The Motley Fool. Athenex, inc (NASDAQ: ATNX) Q2 2021 Earnings Call Aug 6, 2021 , 10:00 p.m. ET Operator Continue reading For further details see: Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...